Switch theme
Sign up to access all valuation multiples
OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.
2016
40
LTM Revenue $74.0M
LTM EBITDA $35.4M
$134M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
OSE Immunotherapeutics has a last 12-month revenue (LTM) of $74.0M and a last 12-month EBITDA of $35.4M.
In the most recent fiscal year, OSE Immunotherapeutics achieved revenue of $78.5M and an EBITDA of $52.0M.
OSE Immunotherapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See OSE Immunotherapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $74.0M | XXX | $78.5M | XXX | XXX | XXX |
| Gross Profit | $74.0M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | $35.4M | XXX | $52.0M | XXX | XXX | XXX |
| EBITDA Margin | 48% | XXX | 66% | XXX | XXX | XXX |
| EBIT | $28.8M | XXX | $33.7M | XXX | XXX | XXX |
| EBIT Margin | 39% | XXX | 43% | XXX | XXX | XXX |
| Net Profit | $25.0M | XXX | $42.1M | XXX | XXX | XXX |
| Net Margin | 34% | XXX | 54% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $29.3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, OSE Immunotherapeutics's stock price is EUR 6 (or $7).
OSE Immunotherapeutics has current market cap of EUR 132M (or $149M), and EV of EUR 119M (or $134M).
See OSE Immunotherapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $134M | $149M | XXX | XXX | XXX | XXX | $1.38 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, OSE Immunotherapeutics has market cap of $149M and EV of $134M.
OSE Immunotherapeutics's trades at 1.7x EV/Revenue multiple, and 2.6x EV/EBITDA.
Equity research analysts estimate OSE Immunotherapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
OSE Immunotherapeutics has a P/E ratio of 6.0x.
See valuation multiples for OSE Immunotherapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $149M | XXX | $149M | XXX | XXX | XXX |
| EV (current) | $134M | XXX | $134M | XXX | XXX | XXX |
| EV/Revenue | 1.8x | XXX | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | 3.8x | XXX | 2.6x | XXX | XXX | XXX |
| EV/EBIT | 4.6x | XXX | 4.0x | XXX | XXX | XXX |
| EV/Gross Profit | 1.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 6.0x | XXX | 3.5x | XXX | XXX | XXX |
| EV/FCF | 3.2x | XXX | 2.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOSE Immunotherapeutics's last 12 month revenue growth is -40%
OSE Immunotherapeutics's revenue per employee in the last FY averaged $2.0M, while opex per employee averaged $1.1M for the same period.
OSE Immunotherapeutics's rule of 40 is -826% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
OSE Immunotherapeutics's rule of X is -53% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for OSE Immunotherapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -40% | XXX | -31% | XXX | XXX | XXX |
| EBITDA Margin | 48% | XXX | 66% | XXX | XXX | XXX |
| EBITDA Growth | -87% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -826% | XXX | 26% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -53% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $2.0M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 44% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 57% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
OSE Immunotherapeutics acquired XXX companies to date.
Last acquisition by OSE Immunotherapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . OSE Immunotherapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was OSE Immunotherapeutics founded? | OSE Immunotherapeutics was founded in 2016. |
| Where is OSE Immunotherapeutics headquartered? | OSE Immunotherapeutics is headquartered in France. |
| How many employees does OSE Immunotherapeutics have? | As of today, OSE Immunotherapeutics has 40 employees. |
| Who is the CEO of OSE Immunotherapeutics? | OSE Immunotherapeutics's CEO is Mr. Nicolas Poirier, PhD. |
| Is OSE Immunotherapeutics publicy listed? | Yes, OSE Immunotherapeutics is a public company listed on PAR. |
| What is the stock symbol of OSE Immunotherapeutics? | OSE Immunotherapeutics trades under OSE ticker. |
| When did OSE Immunotherapeutics go public? | OSE Immunotherapeutics went public in 2015. |
| Who are competitors of OSE Immunotherapeutics? | Similar companies to OSE Immunotherapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of OSE Immunotherapeutics? | OSE Immunotherapeutics's current market cap is $149M |
| What is the current revenue of OSE Immunotherapeutics? | OSE Immunotherapeutics's last 12 months revenue is $74.0M. |
| What is the current revenue growth of OSE Immunotherapeutics? | OSE Immunotherapeutics revenue growth (NTM/LTM) is -40%. |
| What is the current EV/Revenue multiple of OSE Immunotherapeutics? | Current revenue multiple of OSE Immunotherapeutics is 1.8x. |
| Is OSE Immunotherapeutics profitable? | Yes, OSE Immunotherapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of OSE Immunotherapeutics? | OSE Immunotherapeutics's last 12 months EBITDA is $35.4M. |
| What is OSE Immunotherapeutics's EBITDA margin? | OSE Immunotherapeutics's last 12 months EBITDA margin is 48%. |
| What is the current EV/EBITDA multiple of OSE Immunotherapeutics? | Current EBITDA multiple of OSE Immunotherapeutics is 3.8x. |
| What is the current FCF of OSE Immunotherapeutics? | OSE Immunotherapeutics's last 12 months FCF is $42.3M. |
| What is OSE Immunotherapeutics's FCF margin? | OSE Immunotherapeutics's last 12 months FCF margin is 57%. |
| What is the current EV/FCF multiple of OSE Immunotherapeutics? | Current FCF multiple of OSE Immunotherapeutics is 3.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
